Viking Therapeutics: An Equally Important Catalyst Ahead (NASDAQ:VKTX)

Viking Therapeutics ( VKTX ) has already completed enrollment of its VANQUISH-1 study of VK2735 in obesity, and its VANQUISH-2 study in type 2 diabetes/obesity is set to complete enrollment this quarter. Those studies will take 78 weeksScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I ...